SCHEMBL3285239

SCHEMBL3285239

CCn1nc(C)cc1C(N)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
ALDH1A1 P00352 3/20 0.50
NPSR1 Q6W5P4 1/20 0.50
STING1 Q86WV6 8/20 0.47
TBK1 Q9UHD2 1/20 0.47
POLB P06746 2/20 0.47
LMNA P02545 2/20 0.46
KDM4E B2RXH2 1/20 0.45
PKM P14618 1/20 0.45
AURKA O14965 1/20 0.43
CSF1R P07333 1/20 0.43
RET P07949 1/20 0.43
LTK P29376 1/20 0.43
CSNK1A1 P48729 1/20 0.43
CDK8 P49336 1/20 0.43
CLK2 P49760 1/20 0.43
CDK5 Q00535 1/20 0.43
ACVR1 Q04771 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
SMYD3 Q9H7B4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31066894 0.98 MAPT (0.55) MAPTALDH1A1NPSR1STING1TBK1
SCHEMBL8204434 0.85 MAPT (0.56) MAPTALDH1A1NPSR1STING1TBK1
SCHEMBL4007518 0.85 MAPT (0.56) MAPTALDH1A1NPSR1STING1TBK1
SCHEMBL710008 0.85 MAPT (0.56) MAPTALDH1A1NPSR1STING1POLB
SCHEMBL23115923 0.84 ALDH1A1 (0.53) MAPTALDH1A1NPSR1STING1TBK1
SCHEMBL10330272 0.83 MAPT (0.48) MAPTALDH1A1NPSR1STING1TBK1
SCHEMBL8402126 0.83 MAPT (0.55) MAPTALDH1A1NPSR1STING1TBK1
SCHEMBL23115896 0.83 MAPT (0.48) MAPTALDH1A1NPSR1STING1TBK1
SCHEMBL3057252 0.83 MAPT (0.55) MAPTALDH1A1NPSR1STING1TBK1
SCHEMBL26415207 0.83 STING1 (0.43) MAPTALDH1A1NPSR1STING1TBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479858-B2 Macrocyclic compounds as sting agonists and methods and uses thereof LUPIN LIMITED (IN) 2025-11-25 US claimed
EP-4004002-B1 MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF LUPIN LTD (IN) 2024-07-10 EP claimed
CN-114174303-B Macrocyclic compounds as STING agonists and methods and uses thereof 印度鲁宾有限公司 2024-06-25 CN claimed
US-20220289763-A1 Macrocyclic Compounds as Sting Agonists and Methods and Uses Thereof LUPIN LIMITED (IN) 2022-09-15 US claimed
EP-4004002-A1 MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF Lupin Limited (IN) 2022-06-01 EP claimed
CN-114174303-A Macrocyclic compounds as STING agonists, methods and uses thereof 印度鲁宾有限公司 2022-03-11 CN claimed
WO-2001034578-A1 COMPOUNDS WITH ANTI-HELICOBACTER PYLORI ACTIVITY ASTRAZENECA AB (SE) 2001-05-17 WO claimed
US-5126362-A Substituted pyrazoylacetamides NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1992-06-30 US claimed
EP-4695254-A1 SUBSTITUTED 6-IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF Dice Alpha, Inc. (US) 2026-02-18 EP disclosed
US-12479858-B2 Macrocyclic compounds as sting agonists and methods and uses thereof LUPIN LIMITED (IN) 2025-11-25 US disclosed
US-12297190-B2 Modulators of STING (stimulator of interferon genes) PFIZER INC. (US) 2025-05-13 US disclosed
WO-2024215597-A1 SUBSTITUTED 6-IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. (US) 2024-10-17 WO disclosed
CN-118510770-A Fused heteroaryl hydroxamic acids as STING agonists 比西切姆有限公司 2024-08-16 CN disclosed
CN-118401531-A Benzimidazole compound and medical application thereof 中国科学院上海药物研究所 2024-07-26 CN disclosed
US-20050107428-A1 Chemical compounds ASTRAZENECA AB (SE) 2005-05-19 US disclosed
EP-1478624-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2004-11-24 EP disclosed
US-20040077557-A1 Macrolide antibiotics GLAXO GROUP LIMITED (GB) 2004-04-22 US disclosed
EP-1363925-A1 MACROLIDE ANTIBIOTICS GLAXO GROUP LIMITED (GB) 2003-11-26 EP disclosed
WO-2003068743-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2003-08-21 WO disclosed
WO-2002050091-A1 MACROLIDE ANTIBIOTICS GLAXO GROUP LIMITED (GB) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107428-A1 Chemical compounds CCR10, CCR3, CXCR5 MAPT 4845/4885ALDH1A1 3120/4885NPSR1 176/4885
US-12479858-B2 Macrocyclic compounds as sting agonists and methods and uses thereof STING1, CGAS, MAVS MAPT 2326/4885ALDH1A1 4861/4885NPSR1 395/4885
US-12297190-B2 Modulators of STING (stimulator of interferon genes) STING1, IRF3, CGAS MAPT 4588/4885ALDH1A1 4800/4885NPSR1 2257/4885
US-20220289763-A1 Macrocyclic Compounds as Sting Agonists and Methods and Uses Thereof STING1, CGAS, MAVS MAPT 2326/4885ALDH1A1 4861/4885NPSR1 395/4885
US-20040077557-A1 Macrolide antibiotics MALT1, MRPL21, IL1R1 MAPT 3349/4885ALDH1A1 2482/4885NPSR1 1596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.